- Home
- STXS vs FENC Comparison
STXS vs FENC Comparison
Compare STXS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STXS | FENC |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.0M | 258.5M |
| IPO Year | 2004 | 2001 |
Fundamental Metrics
Financial Performance| Metric | STXS | FENC |
|---|---|---|
| Price | $2.37 | $7.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 471.8K | 219.0K |
| Earning Date | 11-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $30,075,000.00 | ★ $38,790,000.00 |
| Revenue This Year | $24.48 | N/A |
| Revenue Next Year | $29.98 | $75.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.62 | N/A |
| 52 Week Low | $1.54 | $4.68 |
| 52 Week High | $3.59 | $9.92 |
Technical Indicators
Market Signals| Indicator | STXS | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 44.44 | 42.20 |
| Support Level | $2.34 | $7.35 |
| Resistance Level | $2.44 | $7.74 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 55.17 | 20.00 |
Price Performance
Historical ComparisonAbout STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.